Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 2/20 | 0.61 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091708 | 0.95 | OPRM1 (0.61) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| SCHEMBL4211121 | 0.95 | OPRM1 (0.61) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| Hydrochloric Acid SCHEMBL4207721 | 0.94 | OPRM1 (0.60) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| Oxalic Acid SCHEMBL4208908 | 0.93 | OPRM1 (0.59) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| SCHEMBL9995201 | 0.92 | UBE2M (0.61) | UBE2MDCUN1D1SLC2A1OPRM1HTR2A | |
| SCHEMBL3707074 | 0.89 | ACHE (0.55) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| SCHEMBL340505 | 0.89 | ACHE (0.55) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| SCHEMBL341808 | 0.85 | SLC2A1 (0.50) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| SCHEMBL5540777 | 0.85 | SLC2A1 (0.50) | UBE2MDCUN1D1SLC2A1MCHR1OPRM1 | |
| SCHEMBL5329449 | 0.84 | HTR2A (0.59) | UBE2MDCUN1D1OPRM1HTR2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| JP-4664564-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1263729-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | claimed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | claimed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | claimed |
| JP-2003531829-A | — | — | 2003-10-28 | — | — | JP | claimed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | claimed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | claimed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | UBE2M 3969/4885DCUN1D1 3664/4885SLC2A1 1598/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | UBE2M 3969/4885DCUN1D1 3664/4885SLC2A1 1598/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | UBE2M 3969/4885DCUN1D1 3664/4885SLC2A1 1598/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | UBE2M 4673/4885DCUN1D1 4348/4885SLC2A1 949/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | UBE2M 4202/4885DCUN1D1 3403/4885SLC2A1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.